Nexvet Biopharma's Series B Round

Nexvet Biopharma raised a round of funding on April 16, 2014.

Nexvet develops monoclonal antibody therapies for companion animals (e.g. dogs and cats) using its proprietary PETisation platform technology, which uniquely produces therapies 100% customized to targ…

Articles about Nexvet Biopharma's Series B Round: